Zetterberg, Henrik

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 518

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder

Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 506

Plasma tau in Alzheimer disease

Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 502

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 494

Microglial activation and tau propagate jointly across Braak stages

Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 490

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 487

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

Gisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine

HIV Research and TreatmentInfectious Diseases and Tuberculosis

Cited by 481

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology

Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Cited by 473

The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease

Vogt, N. M., Romano, K. A., Darst, B. F., Engelman, C. D., Johnson, S. C., Carlsson, C. M., Asthana, S., Blennow, K., Zetterberg, H., Bendlin, B. B., et al. (2018) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 471

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 470

CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease

Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 456

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 439

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 436

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 435

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 426

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 401

Total and phosphorylated tau protein as biological markers of Alzheimer’s disease

Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 389

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia

Clinical Laboratory Practices and Quality ControlAlzheimer's disease research and treatments

Cited by 374

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography

Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 368

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology

Genetic Neurodegenerative DiseasesHereditary Neurological Disorders

Cited by 364

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease

Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 359

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease

Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 359

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 353

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 353